BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(34): 7645-7659 [PMID: 27678348 DOI: 10.3748/wjg.v22.i34.7645] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 72] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Ngo MT, Jeng HY, Kuo YC, Diony Nanda J, Brahmadhi A, Ling TY, Chang TS, Huang YH. The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance. Int J Mol Sci 2021;22:1931. [PMID: 33669204 DOI: 10.3390/ijms22041931] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Yildiz G. Integrated multi-omics data analysis identifying novel drug sensitivity-associated molecular targets of hepatocellular carcinoma cells. Oncol Lett 2018;16:113-22. [PMID: 29930714 DOI: 10.3892/ol.2018.8634] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Ramesh G, Das S, Bola Sadashiva SR. Berberine, a natural alkaloid sensitizes human hepatocarcinoma to ionizing radiation by blocking autophagy and cell cycle arrest resulting in senescence. J Pharm Pharmacol 2020;72:1893-908. [PMID: 32815562 DOI: 10.1111/jphp.13354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lin YJ, Lin CN, Sedghi T, Hsu SH, Gross CP, Wang JD, Wang SY. Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan. PLoS One 2020;15:e0240542. [PMID: 33052942 DOI: 10.1371/journal.pone.0240542] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Choi NR, Kim JY, Hong JH, Hur MH, Cho H, Park MK, Kim J, Lee YB, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol 2022;22:135. [PMID: 35337274 DOI: 10.1186/s12876-022-02210-3] [Reference Citation Analysis]
6 Liu X, Zhu L, Ma J, Qiao X, Zhu D, Liu L, Leng X. Target-specific delivery of siRNA into hepatoma cells' cytoplasm by bifunctional carrier peptide. Drug Deliv Transl Res 2017;7:147-55. [PMID: 27896668 DOI: 10.1007/s13346-016-0348-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
7 Chaudhary K, Poirion OB, Lu L, Garmire LX. Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer. Clin Cancer Res. 2018;24:1248-1259. [PMID: 28982688 DOI: 10.1158/1078-0432.ccr-17-0853] [Cited by in Crossref: 272] [Cited by in F6Publishing: 164] [Article Influence: 54.4] [Reference Citation Analysis]
8 Peng L, Ye R, Zhu X, Xie Y, Zhong B, Liu Y, Li H, Xie B, Ortega A. LINC02273 Promotes Hepatocellular Carcinoma Progression via Retaining β-Catenin in the Nucleus to Augment Wnt Signaling. BioMed Research International 2022;2022:1-9. [DOI: 10.1155/2022/9631036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wang F, Wang J, Ju L, Chen L, Cai W, Yang J. Diagnostic and prognostic potential of serum miR-132/212 cluster in patients with hepatocellular carcinoma.Ann Clin Biochem. 2018;55:576-582. [PMID: 29357677 DOI: 10.1177/0004563218755815] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
10 Cai H, Yang Y, Peng F, Liu Y, Fu X, Ji B. Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells. Int J Med Sci 2019;16:1541-8. [PMID: 31839741 DOI: 10.7150/ijms.37427] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
11 Colagrande S, Calistri L, Grazzini G, Nardi C, Busoni S, Morana G, Grazioli L. MRI features of primary hepatic lymphoma. Abdom Radiol (NY) 2018;43:2277-87. [PMID: 29460044 DOI: 10.1007/s00261-018-1476-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
12 Wang Z, Shi Z, Zhang L, Zhang H, Zhang Y. Profilin 1, negatively regulated by microRNA-19a-3p, serves as a tumor suppressor in human hepatocellular carcinoma. Pathol Res Pract 2019;215:499-505. [PMID: 30638858 DOI: 10.1016/j.prp.2018.12.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
13 Zhang B, Liang Y, Bo L, Chen M, Huang B, Cao Q, Wei J, Li T, Cai X, Ye X. A PCR-free screen-printed magnetic electrode for the detection of circular RNA from hepatocellular cancer based on a back-splice junction. RSC Adv 2021;11:17769-74. [DOI: 10.1039/d1ra01033f] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Liu T, Shi Q, Yang L, Wang S, Song H, Wang Z, Xu X, Liu H, Zheng H, Shen Z. Long non-coding RNAs HERH-1 and HERH-4 facilitate cyclin A2 expression and accelerate cell cycle progression in advanced hepatocellular carcinoma. BMC Cancer 2021;21:957. [PMID: 34445994 DOI: 10.1186/s12885-021-08714-7] [Reference Citation Analysis]
15 Qiu LW, Liu YF, Cao XQ, Wang Y, Cui XH, Ye X, Huang SW, Xie HJ, Zhang HJ. Annexin A2 promotion of hepatocellular carcinoma tumorigenesis via the immune microenvironment. World J Gastroenterol 2020; 26(18): 2126-2137 [PMID: 32476780 DOI: 10.3748/wjg.v26.i18.2126] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
16 Li Y, Han Q, Zhao H, Guo Q, Zhang J. Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma. Front Pharmacol 2020;11:597520. [PMID: 33343368 DOI: 10.3389/fphar.2020.597520] [Reference Citation Analysis]
17 许佐明, 浦涧. CTLs相关的免疫疗法在肝癌治疗中的新前景. 世界华人消化杂志 2017; 25(15): 1389-1395 [DOI: 10.11569/wcjd.v25.i15.1389] [Reference Citation Analysis]
18 Yin L, Xia Y, Xu P, Zheng W, Gao Y, Xie F, Ji Z. Veratramine suppresses human HepG2 liver cancer cell growth in vitro and in vivo by inducing autophagic cell death. Oncol Rep 2020;44:477-86. [PMID: 32468056 DOI: 10.3892/or.2020.7622] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Berasain C, Lechel A. Targeting the correct target in HCC. Gut 2017;66:1352-4. [PMID: 28100646 DOI: 10.1136/gutjnl-2016-313462] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
20 Wang Z, Qu K, Zhou L, Ren L, Ren B, Meng F, Yu W, Wang H, Fan H. Apaf1 nanoLuc biosensors identified lentinan as a potent synergizer of cisplatin in targeting hepatocellular carcinoma cells. Biochem Biophys Res Commun 2021;577:45-51. [PMID: 34507064 DOI: 10.1016/j.bbrc.2021.08.030] [Reference Citation Analysis]
21 Hammond PB, Mark JR, Benefiel RR. Imperial Epistaxis and Edema: Insights into the Death of the Roman Emperor Hadrian. Ear Nose Throat J 2021;:1455613211042120. [PMID: 34448409 DOI: 10.1177/01455613211042120] [Reference Citation Analysis]
22 Xu W, Chen Z, Liu G, Dai Y, Xu X, Ma D, Liu L. Identification of a Potential PPAR-Related Multigene Signature Predicting Prognosis of Patients with Hepatocellular Carcinoma. PPAR Res 2021;2021:6642939. [PMID: 33777129 DOI: 10.1155/2021/6642939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Chu PY, Chan SH. Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5295. [PMID: 34771459 DOI: 10.3390/cancers13215295] [Reference Citation Analysis]
24 Gong ZG, Zhao W, Zhang J, Wu X, Hu J, Yin GC, Xu YJ. Metabolomics and eicosanoid analysis identified serum biomarkers for distinguishing hepatocellular carcinoma from hepatitis B virus-related cirrhosis. Oncotarget 2017;8:63890-900. [PMID: 28969038 DOI: 10.18632/oncotarget.19173] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
25 Xu Z, Yan S, Wu H, Zhang Y, Wei W. Angiotensin II and tumor necrosis factor-α stimulate the growth, migration and invasion of BEL-7402 cells via down-regulation of GRK2 expression. Digestive and Liver Disease 2019;51:263-74. [DOI: 10.1016/j.dld.2018.06.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
26 Ye ZH, Gao L, Wen DY, He Y, Pang YY, Chen G. Diagnostic and prognostic roles of IRAK1 in hepatocellular carcinoma tissues: an analysis of immunohistochemistry and RNA-sequencing data from the cancer genome atlas. Onco Targets Ther 2017;10:1711-23. [PMID: 28356759 DOI: 10.2147/OTT.S132120] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
27 Semaan L, Zeng Q, Lu Y, Zhang Y, Zreik MM, Chamseddine MB, Chopp M, Zhang ZG, Moonka D. MicroRNA-214 enriched exosomes from human cerebral endothelial cells (hCEC) sensitize hepatocellular carcinoma to anti-cancer drugs. Oncotarget 2021;12:185-98. [PMID: 33613846 DOI: 10.18632/oncotarget.27879] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Dai X, Wang S, Niu C, Ji B, Liu Y. Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma. Technol Cancer Res Treat 2020;19:153303382094748. [DOI: 10.1177/1533033820947486] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Shi BM, Lu W, Ji K, Wang YF, Xiao S, Wang XY. Study on the value of serum miR-106b for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2017; 23(20): 3713-3720 [PMID: 28611524 DOI: 10.3748/wjg.v23.i20.3713] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
30 Alqahtani A, Khan Z, Alloghbi A, Said Ahmed TS, Ashraf M, Hammouda DM. Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies. Medicina (Kaunas) 2019;55:E526. [PMID: 31450841 DOI: 10.3390/medicina55090526] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
31 Lee MS, Ryoo BY, Hsu CH, Numata K, Stein S, Verret W, Hack SP, Spahn J, Liu B, Abdullah H, Wang Y, He AR, Lee KH;  GO30140 investigators. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21:808-820. [PMID: 32502443 DOI: 10.1016/s1470-2045(20)30156-x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 63] [Article Influence: 39.0] [Reference Citation Analysis]
32 Wang C, Zhou X, Xu H, Shi X, Zhao J, Yang M, Zhang L, Jin X, Hu Y, Li X, Xiao X, Liao M. Niclosamide Inhibits Cell Growth and Enhances Drug Sensitivity of Hepatocellular Carcinoma Cells via STAT3 Signaling Pathway. J Cancer 2018;9:4150-5. [PMID: 30519314 DOI: 10.7150/jca.26948] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
33 Shugaa Addin AM, Talaat RM, Sakr MA, El Hamshary MO, Khalifa MK, Nasr GM. Identification of the somatic mutations of SMAD4 among HCC Egyptian patients using NGS. Gene Reports 2022;26:101478. [DOI: 10.1016/j.genrep.2021.101478] [Reference Citation Analysis]
34 Zhang K, Fang T, Zhao D, Cen F, Yan X, Jin X. Circular RNA Circ_0008043 promotes the proliferation and metastasis of hepatocellular carcinoma cells by regulating the microRNA (miR)-326/RAB21 axis. Bioengineered 2022;13:6600-14. [DOI: 10.1080/21655979.2022.2044260] [Reference Citation Analysis]
35 Hu S, Zhu Y, Xia X, Xu X, Chen F, Miao X, Chen X. Ginsenoside Rg3 Prolongs Survival of the Orthotopic Hepatocellular Carcinoma Model by Inducing Apoptosis and Inhibiting Angiogenesis. Anal Cell Pathol (Amst) 2019;2019:3815786. [PMID: 31534898 DOI: 10.1155/2019/3815786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Huang J, Chen F, Zhong Z, Tan HY, Wang N, Liu Y, Fang X, Yang T, Feng Y. Interpreting the Pharmacological Mechanisms of Huachansu Capsules on Hepatocellular Carcinoma Through Combining Network Pharmacology and Experimental Evaluation. Front Pharmacol 2020;11:414. [PMID: 32308626 DOI: 10.3389/fphar.2020.00414] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
37 Tang Z, Kang M, Zhang B, Chen J, Fang H, Ye Q, Jiang B, Wu Y. Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma. Tumori 2017;103:286-91. [PMID: 28058713 DOI: 10.5301/tj.5000585] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
38 Wang J, Lou J, Fu L, Jin Q. An independent poor-prognosis subtype of hepatocellular carcinoma based on the tumor microenvironment. J Int Med Res 2021;49:300060520980646. [PMID: 33567957 DOI: 10.1177/0300060520980646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Wei J, Fang D. Endoplasmic Reticulum Stress Signaling and the Pathogenesis of Hepatocarcinoma. Int J Mol Sci 2021;22:1799. [PMID: 33670323 DOI: 10.3390/ijms22041799] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Pan Y, Chen H, Yu J. Biomarkers in Hepatocellular Carcinoma: Current Status and Future Perspectives. Biomedicines 2020;8:E576. [PMID: 33297335 DOI: 10.3390/biomedicines8120576] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
41 Wang X, Zhang Y, Yang N, He H, Tao X, Kou C, Jiang J. Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis. Biomed Res Int 2020;2020:5087643. [PMID: 33015170 DOI: 10.1155/2020/5087643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
42 Jiang Y, Chen P, Hu K, Dai G, Li J, Zheng D, Yuan H, He L, Xie P, Tu M, Peng S, Qu C, Lin W, Chung RT, Hong J. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation. J Cell Mol Med 2021;25:1568-82. [PMID: 33410581 DOI: 10.1111/jcmm.16256] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
43 Kovac JD, Milovanovic T, Dugalic V, Dumic I. Pearls and pitfalls in magnetic resonance imaging of hepatocellular carcinoma. World J Gastroenterol 2020; 26(17): 2012-2029 [PMID: 32536771 DOI: 10.3748/wjg.v26.i17.2012] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Bai J, Liu Z, Liu J, Zhang S, Tian Y, Zhang Y, Ren L, Kong D. Mitochondrial metabolic study guided by proteomics analysis in hepatocellular carcinoma cells surviving long-term incubation with the highest dose of sorafenib. Aging (Albany NY) 2019;11:12452-75. [PMID: 31881007 DOI: 10.18632/aging.102582] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
45 Al Mahtab M, Rahim MA, Noor-E-Alam SM, Alam MA, Khondaker FA, Moben AL, Ghosh J, Khan MSI. Treatment by Transarterial Chemoembolization and Sorafenib for Hepatocellular Carcinoma vs Advanced Hepatocellular Carcinoma in Bangladesh: A Real-life Situation. Euroasian J Hepatogastroenterol 2019;9:63-6. [PMID: 32117692 DOI: 10.5005/jp-journals-10018-1300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Sun W, He B, Yang B, Hu W, Cheng S, Xiao H, Yang Z, Wen X, Zhou L, Xie H, Shen X, Wu J, Zheng S. Genome-wide CRISPR screen reveals SGOL1 as a druggable target of sorafenib-treated hepatocellular carcinoma. Lab Invest 2018;98:734-44. [PMID: 29467456 DOI: 10.1038/s41374-018-0027-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
47 Kim SH, Wang WH, Wang JP, Hsieh CH, Fang K. Teroxirone suppresses growth and motility of human hepatocellular carcinoma cells. Biomed Pharmacother 2018;99:997-1008. [PMID: 29653488 DOI: 10.1016/j.biopha.2018.01.157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
48 Wang ZY, Yang J, Liu CK, Shen SQ. High Expression of Retinoblastoma-Binding Protein 2 (RBP2) in Patients with Hepatocellular Carcinoma and Its Prognostic Significance. Med Sci Monit 2017;23:2736-44. [PMID: 28582381 DOI: 10.12659/msm.905262] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
49 Zhou Y, Liu L, Liu Y, Zhou P, Yan Q, Yu H, Chen X, Zhu F. Implication of human endogenous retrovirus W family envelope in hepatocellular carcinoma promotes MEK/ERK-mediated metastatic invasiveness and doxorubicin resistance. Cell Death Discov 2021;7:177. [PMID: 34238921 DOI: 10.1038/s41420-021-00562-5] [Reference Citation Analysis]
50 Zhuang J, He S, Wang G, Wang G, Ni J, Zhang S, Ye Y, Xia W. Long Noncoding RNA FGFR3-AS1 Promotes Hepatocellular Carcinoma Carcinogenesis via Modulating the PI3K/AKT Pathway. Oncol Res 2018;26:1257-65. [PMID: 29463348 DOI: 10.3727/096504018X15172756878992] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
51 Zhang X, Ma L, Zhai L, Chen D, Li Y, Shang Z, Zhang Z, Gao Y, Yang W, Li Y, Pan Y. Construction and validation of a three-microRNA signature as prognostic biomarker in patients with hepatocellular carcinoma. Int J Med Sci 2021;18:984-99. [PMID: 33456356 DOI: 10.7150/ijms.49126] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Lee BH, Lee DS, Cho CW, Yun SS. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A. World J Surg Oncol 2019;17:143. [PMID: 31416447 DOI: 10.1186/s12957-019-1685-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
53 Du W, Chen W, Shu Z, Xiang D, Bi K, Lu Y, Zhang X, Li L, Diao H. Identification of prognostic biomarkers of hepatocellular carcinoma via long noncoding RNA expression and copy number alterations. Epigenomics 2020;12:1303-15. [PMID: 32772564 DOI: 10.2217/epi-2019-0385] [Reference Citation Analysis]
54 Xu W, Guo W, Lu P, Ma D, Liu L, Yu F. Identification of an autophagy-related gene signature predicting overall survival for hepatocellular carcinoma. Biosci Rep 2021;41:BSR20203231. [PMID: 33351066 DOI: 10.1042/BSR20203231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Zhang B, Chen M, Cao J, Liang Y, Tu T, Hu J, Li T, Cai Y, Li S, Liu B, Xu J, Liang B, Ye X, Cai X. An integrated electrochemical POCT platform for ultrasensitive circRNA detection towards hepatocellular carcinoma diagnosis. Biosens Bioelectron 2021;192:113500. [PMID: 34280653 DOI: 10.1016/j.bios.2021.113500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Liang HW, Ye ZH, Yin SY, Mo WJ, Wang HL, Zhao JC, Liang GM, Feng ZB, Chen G, Luo DZ. A comprehensive insight into the clinicopathologic significance of miR-144-3p in hepatocellular carcinoma. Onco Targets Ther 2017;10:3405-19. [PMID: 28744145 DOI: 10.2147/OTT.S138143] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
57 Suk FM, Liu CL, Hsu MH, Chuang YT, Wang JP, Liao YJ. Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma. Sci Rep 2019;9:17259. [PMID: 31754201 DOI: 10.1038/s41598-019-53863-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
58 Colagrande S, Calistri L, Campani C, Dragoni G, Lorini C, Nardi C, Castellani A, Marra F. CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib. Eur Radiol 2021;31:1608-19. [PMID: 32827266 DOI: 10.1007/s00330-020-07171-3] [Reference Citation Analysis]
59 [DOI: 10.1101/114892] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
60 Wu L, Zhou J, Zhou W, Huang XF, Chen Q, Wang W, Zhai L, Li S, Tang Z. Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo. Pathol Res Pract 2021;220:153270. [PMID: 33640712 DOI: 10.1016/j.prp.2020.153270] [Reference Citation Analysis]
61 Pan X, Kaminga AC, Wen SW, Liu A. Chemokines in hepatocellular carcinoma: a meta-analysis. Carcinogenesis 2020;41:1682-94. [PMID: 33300549 DOI: 10.1093/carcin/bgaa106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
62 Ghorab MM, Ragab FA, Heiba HI, El-Gazzar MG, El-Gazzar MGM. Novel thioureido-benzenesulfonamide derivatives with enaminone linker as potent anticancer, radiosensitizers and VEGFR2 inhibitors. Bioorg Med Chem Lett 2018;28:1464-70. [PMID: 29628325 DOI: 10.1016/j.bmcl.2018.03.089] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
63 Zhao Y, Shuen TWH, Toh TB, Chan XY, Liu M, Tan SY, Fan Y, Yang H, Lyer SG, Bonney GK, Loh E, Chang KTE, Tan TC, Zhai W, Chan JKY, Chow EK, Chee CE, Lee GH, Dan YY, Chow PK, Toh HC, Lim SG, Chen Q. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. Gut 2018;67:1845-54. [PMID: 29602780 DOI: 10.1136/gutjnl-2017-315201] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 19.5] [Reference Citation Analysis]
64 Dong Z, Qi R, Guo X, Zhao X, Li Y, Zeng Z, Bai W, Chang X, Hao L, Chen Y, Lou M, Li Z, Lu Y. MiR-223 modulates hepatocellular carcinoma cell proliferation through promoting apoptosis via the Rab1-mediated mTOR activation. Biochem Biophys Res Commun. 2017;483:630-637. [PMID: 27998765 DOI: 10.1016/j.bbrc.2016.12.091] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
65 Du J, Mao Y, Liu M, Tie Y, Huang H, Zhao J, Xiang Z, Luo D. Dose age affect the efficacy of molecular targeted agents in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget 2017;8:102413-9. [PMID: 29254256 DOI: 10.18632/oncotarget.22061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
66 Xia Y, Liu X, Liu B, Zhang X, Tian G. Enhanced antitumor activity of combined megestrol acetate and arsenic trioxide treatment in liver cancer cells. Exp Ther Med 2018;15:4047-55. [PMID: 29581752 DOI: 10.3892/etm.2018.5905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
67 Gu X, Guan J, Xu J, Zheng Q, Chen C, Yang Q, Huang C, Wang G, Zhou H, Chen Z, Zhu H. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes. J Transl Med 2021;19:26. [PMID: 33407546 DOI: 10.1186/s12967-020-02691-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
68 Chen Z, Zou Y, Zhang Y, Chen Z, Wu F, Shi N, Jin H. A novel prognostic signature based on four glycolysis-related genes predicts survival and clinical risk of hepatocellular carcinoma. J Clin Lab Anal 2021;35:e24005. [PMID: 34523732 DOI: 10.1002/jcla.24005] [Reference Citation Analysis]
69 Wang Y, Chen M, Wu Z, Tong C, Dai H, Guo Y, Liu Y, Huang J, Lv H, Luo C, Feng KC, Yang QM, Li XL, Han W. CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. Oncoimmunology. 2018;7:e1440169. [PMID: 29900044 DOI: 10.1080/2162402x.2018.1440169] [Cited by in Crossref: 82] [Cited by in F6Publishing: 68] [Article Influence: 20.5] [Reference Citation Analysis]
70 Ceballos MP, Rigalli JP, Ceré LI, Semeniuk M, Catania VA, Ruiz ML. ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma. Curr Med Chem 2019;26:1224-50. [PMID: 29303075 DOI: 10.2174/0929867325666180105103637] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
71 Li X, Zhang D, Guan S, Ye W, Liu L, Lou L. Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review. Oncotarget 2017;8:93179-85. [PMID: 29190987 DOI: 10.18632/oncotarget.21452] [Reference Citation Analysis]
72 Keating GM. Sorafenib: A Review in Hepatocellular Carcinoma. Target Oncol. 2017;12:243-253. [PMID: 28299600 DOI: 10.1007/s11523-017-0484-7] [Cited by in Crossref: 95] [Cited by in F6Publishing: 107] [Article Influence: 19.0] [Reference Citation Analysis]
73 Sheng L, Li J, Li N, Gong L, Liu L, Zhang Q, Li X, Luo H, Chen Z. Atractylenolide III predisposes miR-195-5p/FGFR1 signaling axis to exert tumor-suppressive functions in liver cancer. J Food Biochem 2021;45:e13582. [PMID: 33768570 DOI: 10.1111/jfbc.13582] [Reference Citation Analysis]
74 Jin C, Bai L, Lin L, Wang S, Yin X. Paclitaxel-loaded nanoparticles decorated with bivalent fragment HAb18 F(ab')2 and cell penetrating peptide for improved therapeutic effect on hepatocellular carcinoma. Artif Cells Nanomed Biotechnol 2018;46:1076-84. [PMID: 28776396 DOI: 10.1080/21691401.2017.1360325] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
75 Chen G, Mo S, Yuan D. Upregulation Mitochondrial Carrier 1 (MTCH1) Is Associated with Cell Proliferation, Invasion, and Migration of Liver Hepatocellular Carcinoma. Biomed Res Int 2021;2021:9911784. [PMID: 34195286 DOI: 10.1155/2021/9911784] [Reference Citation Analysis]
76 Zhang J, Chen Y, Lin J, Jia R, An T, Dong T, Zhang Y, Yang X. Cyclovirobuxine D Exerts Anticancer Effects by Suppressing the EGFR-FAK-AKT/ERK1/2-Slug Signaling Pathway in Human Hepatocellular Carcinoma. DNA Cell Biol 2020;39:355-67. [PMID: 31913706 DOI: 10.1089/dna.2019.4990] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
77 Chu PY, Tung SL, Tsai KW, Shen FP, Chan SH. Identification of the Novel Oncogenic Role of SAAL1 and Its Therapeutic Potential in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1843. [PMID: 32650537 DOI: 10.3390/cancers12071843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Leone V, Ali A, Weber A, Tschaharganeh DF, Heikenwalder M. Liver Inflammation and Hepatobiliary Cancers. Trends Cancer 2021;7:606-23. [PMID: 33674229 DOI: 10.1016/j.trecan.2021.01.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Campos M, Candelária I, Papanikolaou N, Simão A, Ferreira C, Manikis GC, Caseiro-Alves F. Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study. GE Port J Gastroenterol 2019;26:260-7. [PMID: 31328140 DOI: 10.1159/000493351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]